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Abstract
Background: Succinate is an intermediate of the citric acid cycle as well as an extracellular circulating molecule,
whose receptor, G protein-coupled receptor-91 (GPR91), was recently identified and characterized in several tissues,
including heart. Because some pathological conditions such as ischemia increase succinate blood levels, we
investigated the role of this metabolite during a heart ischemic event, using human and rodent models.
Results: We found that succinate causes cardiac hypertrophy in a GPR91 dependent manner. GPR91 activation triggers
the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2), the expression of calcium/calmodulin dependent
protein kinase IIδ (CaMKIIδ) and the translocation of histone deacetylase 5 (HDAC5) into the cytoplasm, which are
hypertrophic-signaling events. Furthermore, we found that serum levels of succinate are increased in patients with cardiac
hypertrophy associated with acute and chronic ischemic diseases.
Conclusions: These results show for the first time that succinate plays an important role in cardiomyocyte hypertrophy
through GPR91 activation, and extend our understanding of how ischemia can induce hypertrophic cardiomyopathy.
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Background
Cardiac hypertrophy is an adaptive response to biomechan-
ical overload or extracellular stimuli and it is associated with
augmented risk of heart failure and sudden death [1-3]. At
the molecular level, cardiomyocyte hypertrophy is character-
ized by reinduction of the so-called fetal gene program, lead-
ing to upregulation of genes encoding atrial and brain
natriuretic peptides, β-myosin heavy chain and skeletal α-
actin [4]. At the cellular level, increased cell-size and en-
hanced protein synthesis are the prominent characteristics
[5]. Several pathologies including hypertension and ischemic
diseases are known to cause hypertrophy [6-10]. However,
the exact mechanism is poorly understood [11-13].
Succinate is an important intermediate metabolite of
the citric acid cycle and in conditions linked with insuf-
ficient blood supply, such as ischemia, succinate blood
levels may rise [14,15]. The formation of succinate during
ischemia occurs in different ways: in the presence or in
the absence of alpha-ketoglutarate (anaplerotic reaction)
[16,17]. In the reaction in which alpha-ketoglutarate is
present, the reactive oxygen species (ROS) that are in-
creased during ischemia promote decarboxylation of alpha-
ketoglutarate, resulting in a non-enzymatic formation of
succinate that can occur both in the mitochondria and in
the cytosol [17]. In the absence of alpha-ketoglutarate, the
substrates that form succinate are especially amino acids
glutamine and alanine. These amino acids provide one
carbon skeleton for the formation of succinate [14,17-20].
Besides succinate crucial role in energy metabolism, it also
acts as a signaling molecule by binding to and activating its
specific G-protein coupled receptor (GPCR), known as
GPR91 [21]. Signaling pathways triggered by GPR91 include
increases in intracellular Ca2+ and cAMP, as well as activa-
tion of mitogen-activated protein kinases and extracel-
lular signal–regulated kinases-1/2 (MAPK-ERK1/2)
[21-23]. GPR91 was first reported in kidney [21], but
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more recently it was detected in other tissues, including
cardiac muscle [15,21,22]. In cardiomyocytes, succinate
modulates global Ca2+ transients and cell viability
through a PKA-dependent pathway. In this study, we
show for the first time that increased levels of succinate
due to ischemia cause cardiac hypertrophy via GPR91
activation.
Results
Activation of GPR91 by succinate causes cardiomyocyte
hypertrophy likely due to long-term blood pressure
counter regulatory mechanisms
Extracellular accumulation of up to millimolar levels of
succinate is observed in pathophysiological conditions,
such as ischemia [14,15,21]. Moreover, there is a close
correlation between myocardial ischemia and hyper-
trophic cardiomyopathy [24,25]. To investigate whether
succinate causes cardiac hypertrophy, a succinate dose
of 0.066 mg/kg, equivalent to that observed during
ischemic events [15], was administered intravenously to
rats, once a day, for 5 consecutive days. By using perfused-
fixed hearts from PBS (control) and succinate treated ani-
mals, we evaluated changes in cardiomyocyte width from
left cardiac ventricle sections in longitudinal orientation.
Morphometric analysis showed a significant increase in
average myocyte width of groups treated with succinate
compared to controls, (12 ± 0.10 μm in control vs 14.7 ±
0.10 μm in succinate treated animals, p < 0.001), (Figure 1A).
We also observed a significant increase in myocyte nuclear
diameter in succinate treated groups (4.3 ± 0.12 μm in car-
diomyocytes from control animals vs 5.6 ± 0.2 μm in suc-
cinate treated rats, p < 0.001), (Figure 1B), suggesting that
high circulating succinate levels might cause cardiac hyper-
trophy. This finding was confirmed by evaluating the
expression levels of genes expressed during cardiac hyper-
trophy. We detected upregulation of hypertrophic markers
atrial natriuretic peptide (ANP), brain natriuretic peptide
(BNP), and β-myosin heavy chain (MYH7). Moreover we
fond a significant increase in α-skeletal actin (α-SkA)
mRNA levels, a known marker for pathological hyper-
trophy, in heart samples from succinate treated groups.
We observed an increase of 160% in the expression level
of ANP (a.u. = 100 in control cells vs. 260 ± 6.5% in cells
from succinate treated rats, p < 0.001), an increase of
175% in the expression of BNP (a.u. = 100% in cells from
control rats vs 275 ± 10% in cells from succinate treated
rats, p < 0.001), an increase of 125% in the expression of
MYH7 (a.u. = 100% in cells from control rats vs 225 ± 3%
in cells from succinate treated rats, p < 0.001), and increase
of 168% in the expression level of α-SkA (a.u. = 100 in con-
trol cells vs 268 ± 6.3% in cells from succinate treated rats,
p < 0.001) in freshly isolated adult cardiomyocytes from
succinate treated rats when compared to control animals
(Figure 1C-F). Succinate is knows to activate the renin
angiotensin system (RAS) [21], which can modulate blood
pressure [26]. Since sustained increase in blood pressure is
know to cause cardiac hypertrophy [27,28], we investigated
whether the hypertrophy induced by high levels of succin-
ate in the blood stream was a consequence of succinate
triggering changes in the arterial blood pressure. Under
our experimental conditions, we found that the mean
arterial blood pressure (MAP) level was unaffected after
two days of succinate treatment, but slightly increased
at day 4, and reverted to normal values on the final day
of the experiment (day 3: 101.9 ± 0.78 mmHg in control
rats, 109 ± 0.42 mmHg in control rats treated with losartan,
102 ± 1.52 mmHg for succinate-treated rats and 99 ±
3.85 mmHg for rats treated with succinate and losartan, day
4: 101.2 ± 2.86 mmHg in control rats, 95.82 ± 1.88 mmHg in
control rats treated with losartan, 111.6 ± 2.60 mmHg in
succinate-treated rats and 79.92 ± 2.48 mmHg in rats treated
with succinate and losartan, day 5: 98.8 ± 2.94 mmHg in
control rats, 90.43 ± 5.2 mmHg in control rats treated
with losartan,105.3 ± 4.8 mmHg in succinate treated
rats, 77.51 ± 5.79 mmHg in rats treated with succinate
and losartan). These variations occurred without any
change on the heart rate (Figure 2A-D), even though at
the last experimental day, the serum concentration of
succinate was significantly higher in treated animals com-
pared to control (0 mM in control rats vs 0.9 ± 0.13 mM in
succinate treated rats, p < 0.001), (Figure 2E). We noticed
that increases in blood pressure induced by succinate
were reverted by losartan, a well-known inhibitor of
type I angiotensin-II receptor [29]. Additionally, the
consequences of in vivo succinate exposure for cardiac
function were further investigated by echocardiography
experiment in the presence or absence of losartan.
Table 1 shows that succinate increased cardiac output
(52.17 ± 5 in control rats vs 68.03 ± 2.9 in succinate rats,
p < 0.05), left ventricular end diastolic volume (LVd:
180 ± 9.7 in control rats vs 245.20 ± 10.11 in succinate
rats, p < 0.01), stroke volume (SV: 136.7 ± 12.63 in con-
trol rats vs 167.5 ± 7.34 in succinate rats, p < 0.01), and
left ventricular chamber dimension, at both systole (LVIDs:
3.02 ± 0.06 in control rats vs 3.96 ± 0.10, p < 0.01) and dia-
stole (LVIDd: 6.15 ± 0.22 in control rats vs 6.99 ± 0.09,
p < 0.01). Although losartan did not affect most evaluated
parameters, it slightly attenuated succinate-induced in-
crease in left ventricular chamber diameter during diastole
(LVIDd: 6.99 ± 0.09 in succinate rats vs 6.50 ± 0.15 in suc-
cinate + losartan, p < 0.05). Real time PCR of hypertrophic
markers from these experimental groups showed that
losartan partially reverted the re-expression of ANP and
MYH7 induced by succinate. We observed a decreased of
110.7% in the expression level of ANP (a.u. = 304 ± 4.33%
in rats hearts treated with succinate vs. 193.3 ± 6.67% in
rats hearts treated with succinate in the presence of
losartan, p < 0.001), and a decreased of 38.7% in the
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Figure 1 Succinate induces pathologic cardiac hypertrophy. A. Cardiac morphometric analysis after 5 days of consecutive succinate
administration. Upper panels show representative images of cell width. The specimen was stained with hematoxylin and eosin (original
magnification; x 100, scale bars; 50 μm). The bar graph shows quantitative analysis of cardiomyocyte diameter (n = 50, ***p < 0.001). B. The upper
panels show representative images of the nuclear diameter. The bar graph summarizes data from the nuclear diameter. (n = 5, ***p < 0.001). Scale
bar 6 μm. C. ANP mRNA levels in freshly isolated adult cardiomyocytes from control and succinate treated rats. D. BNP mRNA levels in freshly
isolated adult cardiomyocytes from control and succinate treated rats. E. MYH7 mRNA levels in freshly isolated adult cardiomyocytes from control
and succinate treated rats. F. α-SkA mRNA levels in freshly isolated adult cardiomyocytes from control and succinate treated rats. These results
represent the mean ± S.E. of three separate experiments (***p < 0.001).
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expression of MYH7 (a.u. = 174 ± 3.05% in rats hearts
treated with succinate vs 135.3 ± 2.9% in in rats hearts
treated with succinate in the presence of losartan, p < 0.001),
(Additional file 1: Figure S1A-B). Thus, these findings
corroborate previous data showing that succinate acti-
vates RAS [21,23,30]. To address the role of GPR91 on
succinate-induced cardiac hypertrophy, we performed echo-
cardiogram using GPR91 knockout (GPR91 KO) mice.
Table 2 shows that GPR91-KO mice have no alteration in
echocardiographic parameters when compared to wild type.
Despite the absence of GPR91, KO mice treated with suc-
cinate showed changes in left ventricular ejection fraction
(LV-EF 44.33 ± 0.35 in wild mice vs 57.37 ± 0.77 in wild mice
treated with succinate, p < 0.05, and 38.17 ± 1.4 in GPR91
KO mice vs 52.9 ± 4.7 in GPR91 knockout mice treated
with succinate, p < 0.05), fractional shortening (LV-FS:
21.51 ± 0.23 in wild mice vs 29.86 ± 0.23 in wild mice
treated with succinate, p < 0.05, and 18.05 ± 0.70 in
GPR91 knockout mice vs 26.14 ± 2.97 in GPR91 knockout
mice treated with succinate, p < 0.05), and systolic volume
(LV-SV: 32.65 ± 0.65 in wild mice vs 22.13 ± 0.87 in wild
mice treated with succinate, p < 0.01, and 31.43 ± 3.44 in
GPR91 knockout mice vs 17.76 ± 1.36 in GPR91 knock-
out mice treated with succinate, p < 0.01). Importantly,
succinate-induced increase in left ventricular posterior
wall (LVPWs: 0.64 ± 0.09 in wild mice vs 1.05 ± 0.07 in
Figure 2 Sustained levels of serum succinate cause increase in blood pressure on day 4 of treatment, but do not affect heart rate
throughout the experiment. Medium Arterial Pressure levels in control animals and succinate treated animals, with or without IV injection of
losartan on the 3rd day (A), 4th day (B) and 5th day of treatment (C) (**p < 0.01, ***p < 0.001). D. Mean heart rate of control and succinate treated
rats during the experiment. E. Serum succinate concentration measured on the last day of experiment.
Table 1 Echocardiographic parameters
Parameter Control (n = 6) Control + Losartan (n = 3) Succinate (n = 8) Suc + Losartan (n = 5)
Cardiac output (mL/min) 52.17 ± 5.029 52.67 ± 4.7 68.03 ± 2.9* 56.14 ± 3.12
LV ejection fraction (%) 71.74 ± 3.02 75.43 ± 1.78 74.00 ± 1 71.76 ± 1.00
LV fraction shortening (%) 40.95 ± 2.57 45.20 ± 1.81 43.42 ± 0.9 41.87 ± 0.87
LVd (μL) 180.00 ± 9.7 203.90 ± 8.5 245.20 ± 10.11# 209.30 ± 12.09
LV systolic volume (μL) 72.98 ± 6.34 44.64 ± 7.31 62.70 ± 7.53 57.06 ± 3.9
Stroke volume (μl) 136.70 ± 12.63 137.20 ± 12.99 167.50 ± 7.34# 142.10 ± 6.9
Heart rate (bpm) 398.00 ± 9.2 399.40 ± 10.19 402.90 ± 7.9 393.60 ± 17.18
LVIDd (mm) 6.15 ± 0.22 6.32 ± 0.11 6.99 ± 0.09# 6.50 ± 0.15&
LVIDs (mm) 3.02 ± 0.06 3.49 ± 0.14 3.96 ± 0.10# 3.70 ± 0.10*
*p < 0.05 versus control.
&p < 0.05 versus succinate.
#p < 0.01 versus control.
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wild mice treated with succinate, p < 0.05) was observed
only in wild type mice, indicating that GPR91 is essential
for succinate-induced hypertrophic effects on the heart.
We also evaluated the expression levels of the aforemen-
tioned hypertrophic markers in cardiomyocytes isolated
from GPR91 deficient animals. We found that in the
absence of GPR91, injection of succinate was unable to
induce the expression of ANP (a.u. = 100% in cells from
WT mice vs 230 ± 15% in cells from succinate treated WT
mice vs 15 ± 2% in cells from GPR91−/− mice treated with
succinate vs 120% in cells from GPR91−/−, p < 0.001), BNP
(a.u. = 100% in cells from WT mice vs 230 ± 15% in cells
from succinate treated WT mice vs 23 ± 1% in cells from
GPR91−/− mice treated with succinate vs 116 ± 2% in cells
from GPR91−/−, p < 0.001), and MYH7 (a.u. = 100% in
cells from WT mice vs 230 ± 15% in cells from succinate
treated WT mice vs 12 ± 1.4% in cells from GPR91−/−
mice treated with succinate, vs 108 ± 4% in cells from
GPR91−/−, p < 0.001), (Figure 3A-C). The involvement of
other key TCA cycle intermediate was not considered
here since it was already demonstrated that succinate is
the only agonist for GPR91 [21]. Taken together, these
results show that high circulating levels of succinate
lead to cardiac hypertrophy, through direct activation
of GPR91. Nonetheless, the results also suggest that
succinate-induced remodeling is not limited to its dir-
ect effects on the GPR91 in cardiac tissue, but might as
well have its origin point in other organs besides the
heart.
Succinate-induced cardiomyocyte hypertrophy involves
activation of MEK/ERK1/2 and HDAC5 pathways
GPR91 can be coupled with different second messenger
signaling systems, depending on the individual cell type
where it is expressed. For instance, succinate uses both
Gi/Go and Gq/11 pathways to increase ERK1/2 phosphor-
ylation and intracellular Ca2+ [21-23,31], which are, in
fact, pathways involved in cardiac hypertrophy induced by
G-protein coupled receptors [5,13,32,33]. In order to gain
further insight into the mechanisms by which succinate
induces cardiomyocyte hypertrophy and the dependence
of this process on GPR91, we used primary cultures of
Table 2 Echocardiographic parameters
Parameter Control (n = 3) Succinate (n = 3) GPR91 −/− (n = 4) GPR91 −/− + suc (n =3)
Cardiac output (mL/min) 13.09 ± 1.19 13.02 ± 0.46 10.64 ± 0.55 9.18 ± 1.29
LV ejection fraction (%) 44.33 ± 0.35 57.37 ± 0.77* 38.17 ± 1.4 52.9 ± 4.7&
LV fraction shortening (%) 21.51 ± 0.23 29.86 ± 0.23* 18.05 ± 0,70 26.14 ± 2.97&
Interventricular septal
Dimension (diastole, mm) 0.56 ± 0.02 0.54 ± 0.03 0.57 ± 0.05 0.58 ± 0.01
LVd (μL) 3.71 ± 0.03 3.54 ± 0.04 3.72 ± 0.1 3.25 ± 0.12&
LV posterior wall (systole, mm) 0.64 ± 0.09 1.05 ± 0.07* 0.80 ± 0.02 0.75 ± 0.12
LV systolic volume (μL) 32.65 ± 0.65 22.13 ± 0.87# 31.43 ± 3.44 17.76 ± 1.36##
Stroke volume (μl) 25.42 ± 1.01 30.56 ± 0.79 22.88 ± 1.22 20.67 ± 2.41
Heart rate (bpm) 501.2 ± 31 426.1 ± 13 470.7 ± 11 434.6 ± 11.6
Echocardiographic measurements of cardiac parameters in mice following succinate intravenous injection for 5 days.
* < 0.05 versus control.
&p < 0.05 versus GPR91 −/−.
#p < 0.01 versus control.
##p < 0.01 versus GPR91 −/−.
Figure 3 High blood levels of succinate induce cardiac
hypertrophy through GPR91. A-C. ANP, BNP and BNP mRNA levels
in cardiomyocytes from control (WT) and knockout mice (GPR91−/−)
subjected to intravenous administration of succinate for 5 days
(n = 6, ***p < 0.001).
Aguiar et al. Cell Communication and Signaling  (2014) 12:78 Page 5 of 17
neonatal rat cardiomyocytes. We first investigated whether
in vitro succinate treatment could also induce hypertrophy.
For that, we tested several different concentrations of suc-
cinate, and measured cellular width after treatment with
each of these concentrations (500 ± 12 μm2 for control
cells; 682 ± 20 μm2 for cells treated with 25 mM succinate;
800 ± 15 μm2 for 0.5 mM succinate, 1000 ± 15 μm2 for
0.75 mM succinate, 1041 ± 25 μm2 for 1 mM succinate,
1083 ± 13 μm2 for 1.5 mM succinate, 1080 ± 10 μm2 for
2 mM succinate, 1085 ± 20 μm2 for 2.5 mM succinate,
Additional file 2: Figure S2). We found that neonatal cardi-
omyocytes exposed to 1 mmol/L succinate for 36 hours had
increased cell surface area when compared to controls
(600 μm2± 15 in cells from control vs 1100 μm2± 20 in cells
from succinate treated cardiomyocytes, p < 0.01, n = 60
cells), (Figure 4A-B). In addition, succinate treatment led to
an increase in ANP expression levels (a.u. = 0.93 ± 0.06 in
cells from control vs 1.3 ± 0.10 in cells from succinate
treated cardiomyocytes, n = 3 independent experiments,
p < 0.01), (Figure 4C-D), providing evidence for onset car-
diomyocyte hypertrophy, an effect that was not observed
upon knockdown of succinate receptor with GPR91
siRNA. Real time PCR analysis indicated that siRNA
against GPR91 abolished the expression of succinate re-
ceptor (Figure 5A) and prevented the increase of hyper-
trophic markers induced by succinate: ANP (a.u. = 100%
in control cells vs 180 ± 8% in succinate treated cells vs
100 ± 1.4% in cells with GPR91siRNA, p < 0.001) and BNP
(a.u. = 100% in control cells vs 180 ± 8% in succinate
treated cells vs 95 ± 1.4% in cells with GPR91siRNA, n = 3
control succinate
A C
B D
Figure 4 Succinate induces hypertrophy in neonatal cardiomyocytes. A. Representative confocal images of neonatal cardiomyocytes
double-labeled with DAPI (blue), and anti-α-actinin (red). Left panel shows control cells and right panel shows cells treated with succinate.
B. Summary of cellular area, indicating that succinate induces hypertrophy. (*p < 0.05, n = 35 cells). C. Representative immunoblot of whole-cell
protein lysates from neonatal cardiomyocytes probed with anti-ANP and anti-GAPDH. D. Bar graph shows that succinate significantly increases
ANP levels. These results represent the mean ± S.E. of three separate experiments (**p < 0.01).
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independent experiments, p < 0.001), (Figure 5B-C). These
findings show that succinate causes hypertrophy due to a
direct activation of GPR91 in cardiomyocytes.
Because ERK1/2 phosphorylation is a classical MAPK
pathway activated in cardiomyocyte hypertrophy [13,32],
and GPR91 activation is known to be associated with
the ERK1/2 signaling cascade [21,23,31], we investigated
whether succinate treatment alters ERK1/2 phosphorylation
levels in cardiomyocytes as well. We found that exposing
cardiomyocytes to succinate increased phosphorylation of
ERK1/2, without affecting its expression levels (a.u. = 0.58
± 0.02 in control cardiomyocytes vs 0.78 ± 0.02 in succinate
treated cardiomyocytes, p < 0.01, n = 3 independent experi-
ments). We also observed that efficient silencing of
GPR91 prevented the increase in ERK1/2 phosphorylation
upon succinate treatment (a.u. = 0.58 ± 0.02 in control car-
diomyocytes vs 0.89 ± 0.05 in succinate treated cardiomyo-
cytes vs 0.70 ± 0.03 in succinate treated cardiomyocytes
transfected with GPR91siRNA, p < 0.01, n = 3 independent
experiments), (Figure 6A-B). Moreover, the effects of suc-
cinate on cellular area and ANP expression were prevented
by PD098059, an inhibitor of MEK1/2, (a.u. = 100% in
control cells vs 180 ± 12% in cells treated with succinate vs
125 ± 5% in cells treated with succinate in the presence of
PD098059, vs 109 ± 4% in PD098059 treated cells alone;
(fluorescence intensity: a.u. = 62500 ± 500 in control cells
vs 87500 ± 763 in cells treated with succinate vs 50500 ±
10000 in cells treated with succinate in the presence of
PD098059, vs 71000 ± 577% in PD098059 treated cells
alone; n = 45, p < 0.01), (Figure 6C-E). We observed a very
low expression of ANP, close to the control level. Since
PD098059 is specific to MAPK inhibition, this data may
suggest the existence of another protein, downstream to
the MAPK inhibition, that negatively feedbacks the path-
way, inactivating other important intermediate or adding to
MEK inhibition, contributing to the lower activity caused
by PD098059 [34-36]. However, altogether these findings
show that MEK/ERK cascade is a crucial downstream
pathway of the hypertrophic effects induced by succinate.
Additional important signaling cascades that are well-
known to be involved in cardiomyocyte hypertrophy are
the calcineurin-NFAT [2,3] and the histone deacetylase
(HDAC) [37] pathways, both activated upon an increase in
intracellular Ca2+ signals [38]. We have previously demon-
strated that succinate increases intracellular Ca2+ tran-
sients in cardiomyocytes [22]. Thus, we now investigated
whether exposing cardiomyocytes to succinate would trig-
ger the above-mentioned Ca2+-dependent hypertrophic
signaling cascades. We found that succinate did not acti-
vate NFAT, represented by the absence of NFAT in the nu-
cleus upon succinate treatment (Additional file 3: Figure
S3A-B). Instead, succinate activated calmodulin kinase IIδ
(CaMIIδ), (a.u. = 1.75 ± 0.06 in control cells, vs 2.30 ± 0.1
in succinate treated cells, n = 3, p < 0.01), (Figure 7A-B), and
HDAC5 signaling pathway (Figure 7C-E). HDAC5 translo-
cated from the nucleus to the cytosol upon succinate
treatment, an effect that was prevented by KN93, an in-
hibitor of CaMKIIδ [39], (a.u. = 93000 ± 1528% in con-
trol cells, vs 46000 ± 3000% in succinate treated cells, vs
82000 ± 9000% in succinate and KN93 treated cells, vs
93000 ± 2000% in KN93 treated cells alone, p < 0.001,
p < 0.01), (Figure 7C-D). The increase in cellular area
induced by succinate was also prevented by KN93 treat-
ment (a.u. = 100 ± 3.68% in control cells, vs 180 ± 5.45%
in succinate treated cells, vs 117 ± 8.35% in succinate
and KN93 treated cells, vs 114 ± 0.8% in KN93 treated
cells alone, p < 0.001, p < 0.01), (Figure 7E). Part of
KN93 effect on cellular area might be due to its unspe-
cific effect as an antagonist. Validating this signaling
pathway we further found that efficient silencing of
GPR91 prevented both the translocation of HDAC5
from the nucleus to the cytosol (a.u. = 91667 ± 4410 in
control cells, vs 88333 ± 4410 in GPR91 siRNA cells, vs
50667 ± 3480 in succinate treated cells, vs 89667 ± 333.3
in GPR91 siRNA and succinate treated cells, p < 0.001), and
the increase in cellular area induced by succinate (a.u. = 102
± 0.57% in control cells, vs 84 ± 0.57% in GPR91 siRNA
cells, vs 156 ± 2% in succinate treated cells, vs 103.3 ± 8.8%
in GPR91 siRNA and succinate treated cells, p < 0.001),
(Additional file 4: Figure S4A-C). These results indicate that
Figure 5 Hypertrophic effect of succinate in cardiomyocytes
requires GPR91 expression. A. Real time PCR showed significant
knockdown of GPR91 mRNA levels in cells transfected with siRNA
against GPR91 (n = 3 independent experiments, ***p < 0.001). B-C.
Knockdown of GPR91 decreased ANP and BNP mRNA levels. (***p < 0.001).
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succinate causes cardiomyocyte hypertrophy through the ac-
tivation of CaMKIIδ/HDAC5 pathway.
To verify whether succinate triggers similar hyper-
trophic signaling cascades in vivo as well, we intravenously
administered 0.066 mg/kg succinate in 8-week-old rats.
Succinate was injected for 5 days, once a day, and the ex-
pression pattern of phospho-ERK1/2 and changes in intra-
cellular Ca2+ transients were evaluated in freshly isolated
adult cardiomyocytes. We found that high circulating
levels of succinate increased the expression of phospho-
ERK1/2 compared to control cells (a.u. = 1 ± 0.3 in cells
from control rats vs 2 ± 0.25 in cells from succinate
treated cardiomyocytes, p < 0.01, n = 3), (Additional file 5:
Figure S5A-B). We also found that administration of
succinate for 5 consecutive days modulated Ca2+ tran-
sients in isolated ventricular myocytes loaded with the
Ca2+ fluorescent probe fluo-4/AM. As expected, succinate
increased the amplitude (3.8 ± 0.4 F/F0 in cells from con-
trol rats vs 5.2 ± 0.6 F/F0 in cells from succinate treated
cardiomyocytes, p < 0.01, n = 40 cells), and decreased the
decay rate of the Ca2+ transient, (950 ± 9 ms in cells from
control rats vs 920 ± 7 ms in cells from succinate treated
cardiomyocytes, p < 0.05, n = 40), (Additional file 6: Figure
S6A-D). Collectively, these results show that succinate
activates intracellular hypertrophic signaling cascades,
both in vitro and in vivo.
Ischemic diseases increase succinate blood level in patients
Ischemia is known to raise plasma succinate to millimolar
levels in rodents [40]. We now used HPLC to evaluate the
concentration of circulating succinate in human serum.
For that, we first used serum samples of rodents previ-
ously subjected to ischemia-reperfusion procedure, to
standardize the method (p < 0.001, Additional file 7:
Figure S7). We then investigated whether patients with
hypertrophic cardiomyopathy associated with ischemia had
altered levels of succinate in their blood flow. Nine patients
diagnosed with acute myocardial infarction and/or chronic
coronary artery disease showed high blood concentration of
succinate, (0.9 ± 0.1 mmol/L of succinate in serum of
patients with coronary artery disease vs 1 ± 0.2 mmol/L of
succinate in patients with acute myocardial infarction vs
2.69 mmol/L of succinate in patients with myocardial
infarction plus coronary artery disease), compared with 6
control subjects of similar age, with undetectable serum
levels of succinate (Table 3). Moreover, we found elevated
levels of NT–pro–BNP in all subjects with ischemic dis-
ease, although higher levels of NT–pro–BNP were de-
tected in patients with chronic coronary artery disease in
comparison with patients with acute myocardial infarction,
(coronary artery disease: 8101 ± 4524 pg/mL vs 171 ±
101 pg/mL acute myocardial infarction). To verify whether
other more severe acute ischemic conditions could also
cause changes in succinate blood levels, we measured suc-
cinate concentration in the serum of patients that
underwent hepatic transplantation. In these patients,
we evaluated the concentration of succinate 1 hour and
6 hours post transplantation (Table 4). We found that
ischemia-reperfusion injury elevated succinate levels in a
time dependent manner (1.90 ± 0.2 mmol/L of succinate
1 hours post transplantation and 2.36 ± 0.2 mmol/L of
succinate 6 hours post transplantation). More information
about the patients can be seen elsewhere (Additional file
8: Table S1). Although preliminary, these data suggest that
succinic acid accumulation in the blood is a possible marker
to indicate the presence of ischemia and a potential
target to prevent further damage, such as cardiomyocyte
hypertrophy.
Discussion
Cardiomyocyte hypertrophy is among the most common
causes of ischemic heart disease and may result in myo-
cardial infarction, thus promoting further ischemia. Even
though this complex syndrome has been extensively inves-
tigated, there are still many aspects that remain elusive. In
this work, using both human and rodent systems, we
propose that succinate plays a key role in pathological car-
diomyocyte hypertrophy. Moreover, our results shed some
light on the mechanisms by which succinate, through its
specific receptor GPR91 activation, induces hypertrophic
cardiomyopathy.
Hypertrophic stimuli are mediated by several intracellular
signaling cascades that ultimately cause reactivation of fetal
cardiac genes involved in hypertrophy [41,42]. A central sig-
naling cascade that has been implicated in the development
of cardiac hypertrophy is the mitogen activated protein kin-
ase (MAPK) cascade consisting of the kinases rapid activa-
tion of fibrosarcoma (Raf), MAP/ERK kinase (MEK1/2),
and ERK1/2 [43]. HDAC is another well-established ef-
fector in the transmission of cardiac stress to hypertrophic
gene expression. Here we show that activation of GPR91
by succinate causes phosphorylation of ERK1/2, as already
(See figure on previous page.)
Figure 6 Succinate activates the ERK1/2 hypertrophic signaling pathway. A. Immunoblot of whole cell lysates showing increased
phosphorylation of ERK1/2 and absence of phosphorylated ERK1/2 when GPR91 is silenced with siRNA. B. Bar graph shows that succinate
significantly increases phosphorylation of ERK1/2 levels and fails to increase ERK1/2 phosphorylation when GPR91 is efficiently silenced. These
results represent the mean ± S.E. of three separate experiments (**p < 0.01). C. Cells were treated with succinate and ERK1/2 inhibitor PD 098059.
Immunofluorescence staining with DAPI (blue), anti-α-actinin (red) and ANP (green). D-E. Summary of cellular area and fluorescence intensity
indicating that inhibition of ERK1/2 signaling pathway reverses the hypertrophic effect of succinate. (**p < 0.01, n = 50 cells).
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Figure 7 Succinate activates the CaMKIIδ hypertrophic signaling pathway. A. Immunoblot for CaMKIIδ of whole cell lysates from primary
cultures of neonatal cardiomyocytes. B. Bar graph shows that succinate significantly increases CAMKIIδ levels. These results represent the mean ±
S.E. of three separate experiments. (**p < 0.01). C. Representative images of cardiomyocytes immunostained with antibodies against HDAC5 (green),
α-actinin (red) and DAPI (blue). Succinate decreased HDAC5 nuclear export. Scale bar represents 10 μm. KN93 is a selective CaMKIIδ inhibitor. Nuclear
export of HDAC5 induced by succinate is dependent on CaMKIIδ. D. Quantification of the nuclear fluorescence for HDAC5 (*p < 0.05, **p < 0.01).
E. Summary of cellular area (**p < 0.01, ***p < 0.001), 45 cells).
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demonstrated in other cell types [21,23,44]. Additionally,
we found that succinate increased intracellular Ca2+ tran-
sients required for activation of CaMKIIδ and consequent
HDAC5 phosphorylation. The current findings confirm
previous data [21-23,31] and extend them by now showing
for the first time that succinate in vivo also promotes
increases in intracellular Ca2+ transient in ventricular myo-
cytes. Moreover, our results are in agreement with previous
reports that indicate CaMKIIδ as the main pathway in-
volved in pathological hypertrophy [45,46]. Although
ERK1/2 pathway is also known to induce cardiac hyper-
trophy, in part by activating a crosstalk with the calcineurin-
NFAT circuit [47], we found that under our experimental
conditions, succinate did not induce translocation of NFAT
to the nucleus to activate pro-phypertrophic gene expres-
sion. It is known that calcineurin-NFAT signaling is con-
trolled by other kinases that can directly phosphorylate the
N-terminal regulatory domain of NFAT, antagonizing its nu-
clear occupancy [48-50]. Therefore, we cannot rule out that
succinate could activate such kinases in cardiomyocytes,
including JNK, GSK3, and p38. Indeed, activation of p38
pathway by succinate has been demonstrated in other cell
types [30]. In cardiomyocytes, recent study demonstrated
that succinate could activate PI3K/Akt signaling cascade
[51], which is another pathway also implicated in cardiac
hypertrophy [52].
Intravenous administration of succinate increases plasma
renin activity and causes a dose-dependent increase in blood
pressure, that could be blocked by angiotensin-converting
enzyme inhibitors [21,23]. Moreover, high circulating suc-
cinate concentration was detected in spontaneously hyper-
tensive rats [40]. Under our experimental conditions, we
found that the mean arterial blood pressure was high after 4
consecutive days of succinate treatment, and shifted back to
normal values at the final day of the experiment. We have
not investigated the reason for such an oscillatory pattern of
blood pressure, but it is possible that the succinate-treated
animals experienced a type of compensatory response due
to the abnormal succinate exposure. Indeed, blood pressure
adaptation to hormone stimulation is a natural process, and
has been broadly described [53]. Corroborating previous
data, we also found that succinate effects on cardiac func-
tions were partially reverted by an angiotensin-II receptor
antagonist losartan. Losartan prevented the increase in
stroke volume and cardiac output triggered by succinate,
confirming that, at a systemic level, RAS activation plays a
role in succinate-induced change in blood pressure. We also
discovered that losartan partially prevented the expression
of the hypertrophic fetal genes induced by succinate, indicat-
ing that, at least in part, the observed succinate-induced car-
diac remodeling could be a consequence of changes in
blood pressure due to RAS activation. Despite the fact, that
we have shown a significant increase in cardiomyocyte
diameter by morphometric studies, we found no alteration
in LVP wall thickness by echocardiography studies and no
fibrosis in cardiac specimens. Considering these findings,
we believe that we are observing early stages of cardiac
hypertrophy in 5-day succinate treated rats, and we specu-
late that longer exposure to succinate will be necessary in
order to observe substantial pathological indicators of
Table 3 Characteristics of the control patients and cardiac
and plasma levels of succinate
Study characteristics
Number patients, n 15
Control 6
Cardiac 9
Median age, years 62 ± 2.7*
Pathological condition Number of
patients
Coronary artery disease, n 5
Acute myocardial infarction, n 3
Coronary artery disease + Acute myocardial
infarction, n
1
Total 9
Median blood levels NT-pro-BNP (pg/mL)
Coronary artery disease 8101 ± 4524*
Acute myocardial infarction 171 ± 101*
Coronary artery disease + Acute myocardial
infarction
25000
Median blood levels succinate (mmol/L)
Coronary artery disease 0.9 ± 0.1*
Acute myocardial infarction 1 ± 0.2*
Coronary artery disease + Acute myocardial
infarction
2.69
*The results are expressed as mean ± S.E.M.
Table 4 Patients characteristics and serum levels of
succinate post- hepatic transplantation
Study characteristics
Number patients, n 8
Median age, years 46 ± 7*
Pathological condition Number of
patients
Cirrhosis due to hepatitis C 4
Cirrhosis due to Wilson disease 2
Cirrhosis due to alchohol and hepatocellular
carcinoma
1
Cirrhosis due hepatitis C and hepatocellular
carcinoma
1
Total 8
Median blood levels succinate (mmol/L) Median (mmol/L)
1 hour post transplantation 1.90 ± 0.2*
6 hours post transplantation 2.36 ± 0.3*
*The results are expressed as mean ± S.E.M.
Aguiar et al. Cell Communication and Signaling  (2014) 12:78 Page 11 of 17
cardiac hypertrophy. On the other hand, similar 5-day
succinate injection protocol caused significant increase in
cardiac hypertrophy in mice. These differences in the
susceptibility to cardiac hypertrophy, by iv administra-
tion of succinate, could be due to specie-sensitivity. If
directly accessing the effect of succinate in primary culture
of cardiomyocytes, a pathological type of hypertrophy is
clearly demonstrated, by CaMKIIδ activation, as well as
by α − SKA gene reexpression. Nevertheless, both with
in vivo and in vitro studies, our data support a direct role
of GPR91 in succinate-induced cardiac hypertrophy,
since GPR91 ablation prevented: succinate-induced car-
diac hypertrophy in GPR91KO mice, expression of hyper-
trophic markers, ERK1/2 activation, and intracellular
HDAC5 translocation. Even though succinate can induce
cardiac hypertrophy – through systemic augmentation of
renin-angiotensin II activity and local activation of the
above mentioned hypertrophic cellular signaling cascades
in cardiomyocytes – GPR91 is a converting point in both
of them. We still cannot rule out the possibility that
succinate might bind to other not yet characterized recep-
tor(s), which may activate distinct intracellular signaling
pathway to differently regulate cell function.
Myocardial ischemia is accompanied by a variety of
metabolic alterations in myocardial tissue. Succinic acid,
for instance, was observed to accumulate in severely as
well as in moderately ischemic rabbit hearts, with a good
correlation between degree plus duration of myocardial
ischemia and tissue succinate content [54]. Using HPLC
measurements, we now show that upon ischemic injury,
succinate concentration also reaches blood flow. We found
that succinate concentration increases in the serum of pa-
tients with cardiac hypertrophy associated with acute or
chronic obstructive coronary artery diseases. Whether suc-
cinate was among the causes of the cardiac hypertrophy
observed in these patients, or a consequence of the ische-
mic process, or both, still remain to be determined. How-
ever, our data show that succinate induces cardiomyocyte
hypertrophy in cardiac cells though direct GPR91 activa-
tion. Thus, the presence of high circulating levels of suc-
cinate in the blood flow might reinforce the already
installed hypertrophic phenotype that can lead to myocar-
dial infarction, one of the ultimate consequences of ische-
mic heart disease.
High succinate concentrations have been detected in
several other scenarios such as in blood samples from
rodent models of hypertension and metabolic disease
(type 2 diabetes) [40,55], in clinical specimens of patients
with peritonitis [55], as well as in perfusate of rat liver
under hepatic ischemia [15]. In line with these reports,
we found that succinate is also increased in serum of
patients that underwent liver transplant, a process that in-
volves a transitory ischemic condition. Indeed cardiovas-
cular diseases make up the most common cause of death
in patients with functioning allografts at all times after
transplantation, accounting for 30% mortality overall, with
highest rates in the peritransplantation period. Therefore,
GPR91 antagonism in preservation solution for transplant-
ation could represent, for instance, a real benefit to help
preventing cardiac hypertrophy due to organ transplant.
Moreover, during transplant, succinate has been pointed as
an ‘alarming’ signal able to trigger GPR91 to sense im-
munological danger and to increase allograft rejection
[56]. In fact, a multiorgan failure has been reported in a
liver-intestine transplant from a pediatric donor with a
succinate- cytochrome C-reductase deficiency, a condi-
tion that raises succinate blood levels [57]. It has also
been demonstrated that a patient with succinate dehydro-
genase deficiency, another condition that also leads to
extracellular accumulation of succinate, exhibited congest-
ive heart failure [58]. Thus, succinate might be a clinical
marker for ischemia, and its increase at blood level during
organ transplant should be prevented, since it may cause,
among other damages, cardiac hypertrophy.
Conclusions
Collectively, our data strengthen previous results showing
that succinate can be found outside the cell during ische-
mia and act as a circulating hormone. Our results also ex-
pand previous findings by showing that succinate, through
GPR91 activation, induces cardiac hypertrophy. Interfering
with this mechanism might prove as a powerful strategy in
the prevention of cardiac hypertrophy and consequently
heart failure.
Methods
Materials and reagents
Cardiomyocyte primary culture extracting kit was obtained
from Worthington Biochemical Corporation (Lakewood,
USA). Dulbeccos’s Modified Eagle’s Medium (DMEM),
penicillin, streptomycin, amphotericin and fetal bovine
serum (FBS) were purchased from Gibco (Grand Island,
USA). Cytosine β-D-arabinofuranoside (ARA-C), fibronec-
tin, KN-93 (Ca2+/calmodulin-dependent protein kinase II
inhibitor) and ultra-pure succinic acid were obtained from
Sigma (St. Louis, USA), Fluo-4/AM, DAPI and secondary
antibodies conjugated to Alexa-488, Alexa-633 and Silencer
kit were from Ambion, Life Technologies (New York, USA).
Trizol reagent was obtained from Invitrogen (Eugene, USA).
Polyclonal anti- GAPDH, anti- HDAC5, and anti-ANP
antibodies were from Santa Cruz Biotechnology (Santa
Cruz, USA). Monoclonal anti – Phospho-p44/42 MAPK
and polyclonal anti-MEK1/2 were purchased from Cell
Signaling Technology (Boston, USA), monoclonal anti-
CAMK2δ from Abnova (Taipei, Taiwan). Hydromount was
from National Diagnostics (St. Louis, USA). PD- 98059
(MEK 1/2 innhibitor) was from Calbiochem (Germany).
Enhanced chemiluminescence (ECL-plus Western Blotting
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Detection System) and peroxidase-conjugated anti-
bodies were purchased from Amersham Biosciences
(Buckinghamshire, UK). All other reagents were of the
highest quality commercially available.
Human samples
Use of blood samples from patients with acute coronary
disease, acute myocardial infarction and hepatic trans-
plant as well as the term of free and informed consent,
n: 03182712.2.0000.5149 and n: 00907612.0.0000.5149,
respectively, were approved by the Ethics Committee in
Research of UFMG-COEP.
Animals
In this study, we used adult (250 g) and neonatal
(3–5 days old) Wistar rats, acquired from Centro de
Bioterismo (CEBIO) of the Federal University of Minas
Gerais. GPR91−/− mice (C57BL/6 background) were pro-
vided by Novartis. Animals were maintained on a standard
diet and housed under a 12-hour light–dark cycle. All
animal experiments were performed in accordance to
the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH
publication No. 85–23, revised 1996).
Genotyping of mice
Mice were characterized by PCR using genomic DNA
extracted from tail biopsies. DNA was digested with the
REDExtract-N-Amp Tissue PCR Kit (Sigma-Aldrich).
Routine genotyping by PCR was performed using the
following primers: The forward primer sequence was 5′
TTA CGC CAC TGG GAA CTG GA3′ and the reverse
primer sequence was 5′ TTG ATG GCC TTC TGG
GAA CA 3′[56]. Primers for GPR91 were designed using
the software Primer3 based on the sequence deposited
in the NCBI Nucleotide Bank NM_001001518.1.
Adult cardiomyocyte isolation
Adult ventricular myocytes were freshly isolated as previ-
ously described [59,60] from adult Wistar rats previously
treated with 0.066 mg/kg succinate intravenously. Cells
were incubated in DMEM and the experiments were
carried out at room temperature (22-24°C).
Primary culture of neonatal cardiomyocytes
Cardiomyocytes were isolated from hearts of 3–5 days
old Wistar rats according to the manufacturer’s instruc-
tions (Worthington Biochemical Corporation). The rats
were anesthetized with sodium pentobarbital (50 mg/kg
body weight intraperitoneally), and the beating hearts
were removed surgically. Cells were resuspended in
Dulbeccos’s Modified Eagle’s Medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS), 100 units/ml
penicillin, 100 μg/ml streptomycin and 0.25 μg/ml
anfotericin-b. Cardiomyocytes were plated into fibronectin-
coated culture dishes or flasks, and incubated at 37°C in a
5% CO2 incubator. Two days after plating, cells were
rinsed with DMEM and fed for another 24 h with regu-
lar culture medium, now including 20 μg/ml cytosine
β-D-arabinofuranoside (ARA-C). The ARA-C was added
to the culture medium for 48 h to inhibit growth of non-
cardiomyocyte cells. The medium was then replaced with
FBS-free DMEM with or without succinate (1 mmol/L)
for 12 h and subsequently changed to 10% FBS-containing
medium with or without succinate (1 mmol/L) for 24 h.
Cardiomyocytes were used in experiments at the fourth
day of culture. At this point, there were approximately
5-6 × 104 cardiomyocytes per culture dish, which com-
prised approximately 95% the total cell population
[22,59,61]. The cells were then used for immunofluor-
escence, western blot or qRT-PCR analysis.
Preparation of siRNA
Potential target sites within the GPR91 gene were selected
and then searched with NCBI Blast to confirm specificity
for the receptor. The siRNAs for GPR91, and a siRNA
containing the same nucleotides for GPR91 but in a
scrambled sequence were prepared by a transcriptional-
based method using the Silencer kit, according to the
manufacturer’s instructions. The sense and antisense oli-
gonucleotides of siRNA were, respectively: 5′ AAT CTC
TAA TGC CAG CCA ATT CCT GTC TC 3′ and 5′
AAA ATT GGC TGG CAT TAG AGA CCT GTC TC 3′.
For siRNA studies, day 4 neonatal cardiomyocyte cultures
were treated with 100 nM of each siRNA [22]. We used
single wall carbon nanotubes (CNT) to deliver siRNA and
silence GPR91, as previously described [62]. Cardiomyo-
cytes were incubated at 37°C in an atmosphere of 5% CO2
for 48 hours prior to use.
Western blotting
Cardiomyocytes were harvested as described and protein
content was quantified according to Bradford protein
assay. For ANP, 50 μg of whole cell proteins were sepa-
rated by 12% SDS-PAGE. For GAPDH detection, mouse
monoclonal anti-GAPDH antibody was used at a dilution
of 1:1500. For ERK 1/2 detection, a rabbit polyclonal anti-
body was used at dilution of 1:500. For ANP detection
rabbit polyclonal anti-ANP was used at a dilution of 1:200.
For Phospho-p44/42 MAPK (ERK1/2) detection, a rabbit
monoclonal antibody was used at a dilution of 1:1000. For
CaMKIIδ detection, a mouse monoclonal anti- antibody
was used at a dilution of 1:500. The antibody incubation
proceeded for 2 h at room temperature. After washing,
blots were incubated in HRP-conjugated goat-anti-mouse
or rabbit IgG1 secondary antibody at a dilution of 1:5000
at room temperature for 1 h. Immunodetection was car-
ried out using enhanced chemiluminescence [22,59].
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Immunofluorescence
Confocal immunofluorescence was performed as described
[22,59]. Briefly, cardiomyocytes were seeded onto 6 well
culture dishes, treated with succinate 1 mM and 36 hours
later were fixed with 4% paraformaldehyde, permeabilized
with PBS 1X/Triton 0.5% and non-specific binding was
blocked (PBS, BSA 10%, Triton 0.5%, goat serum 5%) for
1 hour. Cells were then incubated with anti-ANP (1:10),
anti α-actinin (1:150), anti-HDAC5 (1:50) or with anti-
NFAT (1:50) for 2 hours at room temperature. This was
followed by incubation with specific secondary antibodies
conjugated with Alexa-Fluo 488 or 633 (1:500) for 1 hour.
Images were obtained using Zeiss LSM 510 confocal micro-
scope (Thornwood, USA) [22,59].
Measurement of intracellular Ca2+
Intracellular Ca2+ was monitored in individual cardiomyo-
cytes by line scanning and time lapse confocal microscopy
as described previously [22,59,60]. Briefly, adult cardio-
myocytes were incubated with Fluo-4/AM (6 μmol/L) for
30 minutes at 37°C. Coverslips were transferred to a per-
fusion chamber on the stage of a Zeiss LSM510 confocal
microscope. Cells were electrically stimulated at 1 Hz to
produce steady-state conditions. Fluo-4 was excited at
488 nm and observed at 505–550 nm. Increases in Ca2+
were expressed as percent increase in Fluo-4 fluorescence
over baseline [22,63,64].
PD 98059 (MEK 1/2 inhibitor), KN93 (Ca2+/calmodulin-
dependent kinase II inhibitor) and losartan (AT1
angiotensin II receptor antagonist)
10 μmol/L of PD or 1 μmol/L KN93 [39] was added
combined of 1 mmol/L succinate to the cells. Losartan
was administrated in the drinking water, once a day, for
5 days at doses of 200 mg/l [65].
Intravenous administration of succinate and
measurement of arterial blood pressure
Animals were housed in a temperature-controlled room
under a 12 hour light–dark cycle with water and standard
rodent chow available ad libitum. Rats and mice under keta-
mine and xylazine anesthesia had the femoral vein catheter-
ized for intravenous injection of succinate (0.066 mg/kg in
rats and 0.039 mg/kg in mouse) or PBS. Blood pressure was
measured in unanesthetized animals by the tail-cuff method,
MAP was recorded in rats for 5 days; at least 15 measure-
ments were made daily with a BP-2000 blood pressure
analysis tail-cuff System (isitech Systems). The mean
systolic blood pressure and pulse rate were taken for
each animal [21,66].
Real-time PCR
Total RNA was isolated from adult and neonatal cardiomyo-
cytes using TRIzol and cDNA synthesized using SuperScript
II kit (Invitrogen). DNA templates were amplified by
real time PCR on the StepOnePlus™ Real-Time PCR
Systems (Applied Biosystems, CA) using the SYBR
green method, as described. Sequence of the primers used
are: ANP FW: 5′-GGATTTCAAGAACCTGCTAGA-3′
and RE 5′-CTTCATCGGTC TGCTCGCTCA-3′; BNP5′
AGACCACCGCTC TTGTGTGTG-3′ and RE 5′ CTGAC
C CATACCTACCATGACACC-3′; MHC and GPR91 FW:
5′-TTACGCCACTGGGAACT GGA-3′ and RE 5′-TTGA
TGGCCTTCTGGGAACA-3 [22,61,67]: FW: 5′-CAG
GCGGTGCTGTCTCTCTAT-3′ and RE: 5′-GGCAGGG-
CATAACCCTCATA-3′ for α-SkA [61]. Experiments were
performed in triplicate for each data point.
Tissue preparation
After administration for 5 days succinate the rats were
weighed, anesthetized (i.p. sodium pentobarbital 80 mg/
BW plus ketamine chloridrate 10 mg/BW) and perfused
intracardially with Ringer’s solution followed by 10%
neutral buffer formalin (NBF). After fixation, the heart
was removed, weighted and the relative organ weight
was calculated per 100 g of body weight. Fragments of
the heart were embedded in paraffin, sectioned (5 μm)
and mounted in silanized glass slides. For histological
and morphometric studies, the sections were stained
with hematoxylin and eosin or Masson’s trichrome [68].
Morphometry
The quantitative analysis of myocyte cross-sectional height
and nuclear diameter were measured in histological sec-
tions by using computer-assisted image analysis and the
Scion Image software (http://www.scioncorp.com), as previ-
ously described [68]. For this purpose, digital images were
obtained with a Nikon Coolpix 995 digital camera (Nikon
Instruments Inc., Melville, USA).
HPLC analysis
Serum samples from humans were collected to determine
succinate using HPLC as previously described [69]. Mice
samples were collected under CO2 euthanasia, while hu-
man samples were collected from conscious individuals.
All subjects had documented coronary atherosclerosis.
Accurate details about the inclusion and exclusion criteria
for this trial were previously published. All human sub-
jects gave written informed consent, and the study was ap-
proved by the Institutional Review Committees at all sites.
Echocardiography
Animals were anaesthetized using a nose cone with isoflur-
ane at 5% for one minute and the maintenance dose was
1.25%. The anterior chest was shaved, and the animals were
placed in supine position on an imaging stage equipped with
built-in electrocardiographic electrodes for continuous
heart rate monitoring and a proper heating pad to avoid
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hypothermia. In vivo cardiac function was assessed noninva-
sively using a high-frequency, high-resolution echocardio-
graphic system consisting of a VEVO 2100 ultrasound
Machine equipped with a 30–40 MHz bifrequencial trans-
ducer (Visual Sonics, Toronto, Canada). High-resolution
images were obtained as previously described [70-73].
Statistical analysis
Results are expressed as mean values ± S.E., except where
otherwise noted. Prism (GraphPad Software, San Diego,
CA) and Image J (NIH; Bethesda, MD) were used for data
and image analysis, respectively. Statistical significance
was tested using One-way ANOVA followed by Bonfer-
roni test, and p value < 0.05 was taken to indicate statis-
tical significance.
Additional files
Additional file 1: Figure S1. Losartan partially reverted expression of
ANP and MYH7 induced by succinate. A. ANP mRNA levels in freshly
isolated adult cardiomyocytes from control, control with losartan,
succinate treated and succinate treated in the presence of losartan rats.
B. MYH7 mRNA levels in freshly isolated adult cardiomyocytes from
control, control with losartan, succinate treated and succinate treated in
the presence of losartan rats. (control n = 6, control + losartan n = 3,
succinate n = 8 and succinate + losartan n = 5, ***p < 0.001).
Additional file 2: Figure S2. Succinate induces hypertrophy
concentration dependent. A. Graph show different concentrations of
succinate, and cellular width (500 ± 12 μm2 for control cells; 682 ± 20 μm2
for cells treated with 25 mM succinate; 800 ± 15 μm2 for 0.5 mM
succinate, 1000 ± 15 μm2 for 0.75 mM succinate, 1041 ± 25 μm2 for 1 mM
succinate, 1083 ± 13 μm2 for 1.5 mM succinate, 1080 ± 10 μm2 for 2 mM
succinate, 1085 ± 20 μm2 for 2.5 mM succinate).
Additional file 3: Figure S3. Succinate does not activate NFAT. Top:
representative images of cardiomyocytes immunostained with
antibodies against NFAT (green), α-actinin (red) and DAPI (blue). Scale
bar represents 10 μm. Bottom: Quantification of NFAT nuclear fluorescence
(p > 0.05, n = 45 cells).
Additional file 4: Figure S4. Silencing of GPR91 prevented the
translocation of HDAC5 and the increase in cellular area induced by
succinate. A. Representative images of cardiomyocytes immunostained
with antibodies against HDAC5 (red) and α-actinin (green). Silencing of
GPR91 prevented the translocation of HDAC5 from the nucleus to the
cytosol . Scale bar represents 10 μm. B. Quantification of the nuclear
fluorescence for HDAC5 (***p < 0.001), n = 30 cells). C. Quantification of
the cellular area. (**p < 0.01).
Additional file 5: Figure S5. Intravenous administration of succinate
alters phosphorylation levels of ERK1/2. Top: representative immunoblot
of whole-cell protein lysates from ventricular cardiomyocytes probed with
anti-phospho ERK1/2 at Thr 202/Tyr204 site and anti-ERK/1/2. Bottom: Bar
graph shows that succinate significantly increases ERK1/2 phosphorylation
levels. These results represent the mean ± S.E. of three separate experiments
(**p < 0.01).
Additional file 6: Figure S6. Intravenous administration of succinate
alters global Ca2+ transients in adult ventricular cardiomyocytes. A - D.
Global Ca2+ transients in freshly isolated adult rat cardiomyocytes. Cai
2+
was monitored with Fluo-4/AM using confocal linescanning microscopy.
Cells were examined after intravenous administration of succinate and
compared to control. Images are pseudocolored according to the color
scale shown at the right of panel A. Tracing under each panel shows the
percent increase in fluorescence relative to baseline, and is representative
of the indicated cell. E- F. Summary of succinate effects on Ca2+ transient
amplitude. Ca2+ kinetics of decay (presented as T90) was significantly
faster in cells after succinate treatment when compared to controls.
(***p < 0.001, *p < 0.05).
Additional file 7: Figure S7. Succinate increases in the serum of mice
subjected to ischemia and reperfusion. A. The bar graph shows the mean
concentration of succinate in the serum of control mice, sham and
animals subjected to liver ischemia and reperfusion, (n = 3, p < 0.001).
Additional file 8: Table S1. Additional health conditions and
characteristics of the cardiac patients.
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